secwatch.observer — SEC 8-K summary
======================================

Issuer:     Connect Biopharma Holdings Ltd (CNTB)
CIK:        0001835268
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001835268-25-000029
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Connect Biopharma starts Phase 2 COPD study of rademikibart, topline data expected 1H 2026
--------------------------------------------------------------------------------

- Phase 2 Seabreeze STAT COPD study initiated after FDA agreement on final protocol.
- Study evaluates single-dose rademikibart vs placebo as adjunct to standard of care for acute COPD exacerbations.
- Approximately 160 participants with type 2 inflammation (eosinophils ≥300 cells/μL) will be enrolled.
- Primary endpoint: treatment failure rate over 28 days; topline data expected in first half of 2026.
- Post-hoc analysis of prior Phase 2b asthma data in COPD-like patients to be presented at ATS 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835268/000183526825000029/0001835268-25-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835268/000183526825000029/cntb-20250514.htm
  HTML page:      https://secwatch.observer/filing/0001835268-25-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer